IO-INTERACTIVE
17.1.2024 15:01:33 CET | Business Wire | Press release
IO Interactive, the independent video game developer and publisher best known for the Hitman and Freedom Fighters franchises, announces today that Veronique Lallier will be joining IOI as its new Chief Development Officer. Operating globally across all studios and situated in Brighton which opened in July 2023, Veronique will be charged with overseeing IOI’s game development strategy and production.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116212318/en/
Veronique Lallier (Photo: IO Interactive)
"I'm excited to join IO Interactive, an iconic game studio with a 25-year legacy of maintaining high standards and creating globally recognized franchises. With exciting projects underway and new studios opening across Europe, I look forward to playing a role in IOI's continued growth and success," shared Veronique Lallier.
Veronique brings with her a wealth of experience in the gaming industry with prior roles in leading video game studios such as Hi-Rez Studios, serving as COO and Studio GM; Warner Bros. Interactive Entertainment as Vice President of Digital Publishing; NCSoft as Studio Managing Director but also Rockstar Games and Ubisoft.
“We are glad to welcome Veronique to IOI. She will bring immense experience, having assumed senior roles in household names in the gaming industry both in Eastern and Western studios. Her background in marketing, publishing, and production is a great blend and makes for a unique profile who will be a tremendous asset for our teams as we look to grow and diversify our IPs,” said Hakan Abrak, CEO of IO Interactive.
The team at the newly opened IOI Brighton studio has hit the ground running since last July and is fully integrated into the development process of the projects currently underway at IO Interactive. Adhering to IOI’s philosophy of working on any project from any studio, the Brighton team has already joined working on Project 007, the first James Bond origin story; Project Fantasy, an online fantasy RPG; and HITMAN World of Assassination.
Building upon the core team already in place, IOI’s ambition for its Brighton studio is to expand over the next year and welcome new talent from the exciting UK development scene with 100 positions now open in various roles. IOI is thus carrying on its organic growth which has been building up for the last few years, with the independent developer and publisher looking to bolster its teams.
With now five studios up and running in Copenhagen, Malmö, Barcelona, Istanbul, and Brighton, IOI is gearing up to be in full force to deliver ambitious and innovative new IPs, after the great success brought about by the completion of the HITMAN trilogy.
Join the IO Interactive journey today and browse our open jobs on our website: www.ioi.dk/careers
ABOUT IO INTERACTIVE
IO Interactive is an independent videogame developer and publisher with studios in Copenhagen, Malmö, Barcelona, Istanbul, and Brighton. As the creative force behind some of the most talked-about multiplatform video games in the last two decades, IOI is dedicated to creating unforgettable characters and experiences using their award-winning proprietary Glacier technology.
IO Interactive will develop and publish the very first James Bond origin story with the working title Project 007 and is currently developing a new IP under the codename Project Fantasy. For more information, visit https://ioi.dk.
© 2024 IO Interactive A/S. IO Interactive and the IOI logo are registered trademarks of IO Interactive A/S.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116212318/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom